FindMyKOL
Clinical trialNCT04052412UnknownPhase 1Interventional

Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer

NCT04052412 is a phase 1 interventional trial sponsored by University of Tennessee. As of 21 Nov 2026, it has a status the registry marks as unknown. It studies 18F-AraG in Non-small Cell Lung Cancer. The registry lists an enrollment of 2 participants at 1 site in 1 country. The registry lists a start date of 16 Jul 2019 and a primary completion date of 31 Dec 2023.

SponsorUniversity of Tennessee →Enrollment2Non-small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04052412
FieldValue
Registry IDNCT04052412
StatusUnknown
PhasePhase 1
Study typeInterventional trial
Lead sponsorUniversity of Tennessee
Enrollment2
Registered sites1
Countries1
ConditionsNon-small Cell Lung Cancer
Drugs18F-AraG
Start16 Jul 2019
Primary completion31 Dec 2023
Study completion31 Dec 2023
Last update posted13 May 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is to assess the biodistribution and kinetics of a novel T-cell imaging agent in non-small cell lung cancer patients undergoing immunotherapy with and without adjuvant radiation therapy. This study is assessing the change in kinetics that occurs in this patient population to better understand the distribution of this compound in patient disease circumstances.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Tennessee, United States1 site, 1 recruiting
  • University of Tennessee Medical Center

    Knoxville

    Dustin Osborne, PhDFrancis J Turner, MDJacob Noe, MDJoseph Kelley, MDYitong Fu, MD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennessee: 1 site, 1 recruitingTN1North CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

18F-AraG
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04052412

Each answer restates registry values shown on this page.

What is NCT04052412?

NCT04052412 is a phase 1 interventional trial sponsored by University of Tennessee. It studies 18F-AraG in Non-small Cell Lung Cancer.

Who leads NCT04052412?

The registry names Dustin Osborne, PhD (principal investigator, University of Tennessee) as the overall official.

Where does NCT04052412 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04052412 study?

The registered drug and biological interventions are 18F-AraG.

When is NCT04052412 expected to complete?

The registry lists a primary completion date of 31 Dec 2023 and a study completion date of 31 Dec 2023. The sponsor last updated the record on 13 May 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.